Indications
Capmatinib Hydrochloride is used to treat adults with metastatic non-small cell lung cancer (NSCLC). It is for people whose tumours have a mutation that causes mesenchymal-epithelial transition (MET) exon 14 skipping, and the mutation must be detected by an FDA approved test.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Capmatinib is a kinase inhibitor that targets MET, including the mutant variant produced by exon 14 skipping. When MET exon 14 skipping happens, the protein that results is missing a regulatory domain. Its negative regulation is reduced, so the signaling downstream of MET increases.
Capmatinib inhibited the growth of cancer cells driven by a mutant MET variant lacking exon 14, at clinically achievable concentrations. It also showed anti-tumor activity in murine tumor xenograft models derived from human lung tumors, either with a mutation leading to MET exon 14 skipping or with MET amplification. It inhibited the phosphorylation of MET triggered by binding of hepatocyte growth factor or by MET amplification. The same was true for MET mediated phosphorylation of downstream signaling proteins, and for the proliferation and survival of MET-dependent cancer cells.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.